Recombinant adenovirus as a fast-acting universal influenza A vaccine
$123,500Y01FY2009AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Abstract
Provide a more rapid approach to containing influenza threats than measures based on the hemagglutinin (HA) and neuraminidase (NA) of particular strains.
View original record on NIH RePORTER →